Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia

Kamil, Muhammad; Yusuf, Nahid; Khalid, Imran Abdul; Islam, R; Biswas, M; Hashim, Hasnah

doi:10.4038/cmj.v55i1.1701

Cited by 10 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding was further supported by a group from Indore city Central India which showed 40.2% positivity and Varanasi city from Northern India exhibited 46.3% positivity (Kumar et al, 2007;Munjal et al, 2009). Reports from Asian , 2006;Naeem et al, 2008;Kamil et al, 2010). Studies from USA have reported that 17-27% of the BC patients are positive for HER-2/neu expression (Taucher et al, 2003;Huang et al, 2005;Lal et al, 2005), while 15-20% of BC cases were reported to be HER-2/neu positive in UK (Lovekin et al, 1991).…”

Section: Discussionmentioning

confidence: 99%

HER-2/neu Status: A Neglected Marker of Prognostication and Management of Breast Cancer Patients in India

Zubeda¹,

Kaipa²,

Shaik³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Categorizing breast tumors based on the ER, PR and HER/Neu 2 receptor status is necessary in order to predict outcome and assist in management of breast cancer. Herfe we assessed this question in South Indian patients. Materials and Methods: A total of 619 formalin fixed paraffin embedded breast tumor tissues were collected from pathology archives after receipt of ethical clearance. With the help of primary and secondary conjugated antibodies, expression status of ER, PR and HER2/neu was determined. All the experimental data were assessed for correlations with histopathological features of tumors and clinical presentation of the subjects. Results: In the present study, the ages ranged from 20-87 years with a mean of 50.0±12.q years, and majority of the tumors (84%) were of infiltrating duct cell carcinoma type. Assessment of ER, PR and Her-2/neu expression showed that 46% were triple negative. Interestingly, an inverse relation between ER, PR and HER-2/neu was apparent in 41.2% (p<0.0001) of the tumors, of which 24.5% (p<0.0001) were ER and PR co-negative but HER-2 positive. Conclusions: ER and PR positive tumors are less common (i.e<30%) compared to HER-2/neu positive tumors (i.e>50%) in Indian breast cancer patients, underlining the need for effective diagnostic screening and specific therapeutic managements in order to improve the survival rate of patients in low resource countries such as India.

show abstract

Section: Discussionmentioning

confidence: 99%

HER-2/neu Status: A Neglected Marker of Prognostication and Management of Breast Cancer Patients in India

Zubeda¹,

Kaipa²,

Shaik³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In a very recent study, overexpression of HER2 protein in two hundred patients in northern Malaysia was not significantly associated with age but that a high percentage (i.e.75%) of overexpression was noted in the age group 81-85 years [164]. Higher rates of HER2 overexpression in postmenopausal women were also seen in breast cancer patients in the south of Switzerland [170].…”

Section: Her2 Statusmentioning

confidence: 93%

“…Another cohort study with 1,359 cases reported that 35.1% of breast cancers in Vietnamese patients had HER2 protein overexpression which is considerably higher compared to results from Western countries [149] [164]. A protein overexpression of HER2 was detected in 32% and gene amplification in 37.5% of cases reported in breast cancers from Thailand [41,165].…”

Section: Her2 Statusmentioning

confidence: 99%

“…Overexpression of HER2 protein was correlated with unfavorable factors such as lymph node positivity and large tumor size [40,41,74]. HER2 positivity was also significantly associated with the Nottingham histological grade III (p<0.001), ER negativity (p<0.001), PR negativity (p<0.001) [53,164]. The HER2 gene amplification was more frequent in tumors with hormone receptor negativity, high grade, and high cell proliferation, but not related to age and tumor size [74,171].…”

Section: Her2 Statusmentioning

confidence: 99%

See 1 more Smart Citation

HER2status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhancedin situhybridization (SISH)

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Positive ER and PR status was determined when immunostaining was positive in ≥ 1% of the cells [ 42 ]. HER2−positive cancers were defined by either strong membrane staining (3+) observed by IHC or amplification of HER2 confirmed by fluorescence in situ hybridization when immunohistochemistry detected moderate (2+) membrane staining [ 43 ].…”

Section: Methodsmentioning

confidence: 99%

Luminal B breast cancer: patterns of recurrence and clinical outcome

et al. 2016

Oncotarget

View full text Add to dashboard Cite

In recent years, most studies on breast cancer relapse and metastasis have focused on non-luminal breast cancers (including the basal-like and HER-2 subtypes) because of their poor prognosis. However, the luminal B subtype is more common, but this type has not been investigated as thoroughly. In the current study, we collected data on 258 patients with luminal-B breast cancer patients with recurrence and metastasis served as the observation group, and 189 patients with non-luminal breast cancer during the same period served as the control group. This study aimed to investigate the pattern of recurrence and clinical outcome after follow-up treatment for luminal B breast cancer. We found a higher proportion of local recurrence and single bone metastasis in patients with luminal B breast cancer than in patients in the non-luminal groups. The risk of recurrence and metastasis in patients with luminal B breast cancer during a 2- to 5-year period and after 5 years was still present, but the risk in patients with non-luminal breast cancers had obviously decreased during the same period. Patients with luminal B breast cancer with recurrence or/and metastasis had a better prognosis after reasonable treatment. The recurrence patterns and clinical outcomes of patients with luminal B breast cancer according to HER2 status were also different, to some degree. These results are of potential clinical relevance especially for the monitoring of clinical prognosis and targeted therapy intervention for luminal B breast cancer.

show abstract

Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia

Cited by 10 publications

References 17 publications

HER-2/neu Status: A Neglected Marker of Prognostication and Management of Breast Cancer Patients in India

HER-2/neu Status: A Neglected Marker of Prognostication and Management of Breast Cancer Patients in India

HER2status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhancedin situhybridization (SISH)

Luminal B breast cancer: patterns of recurrence and clinical outcome

Contact Info

Product

Resources

About